Velan Capital Investment Management LP Acquires New Position in Perspective Therapeutics, Inc. (NYSE:CATX)

Velan Capital Investment Management LP purchased a new position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 500,000 shares of the company's stock, valued at approximately $1,595,000. Perspective Therapeutics accounts for about 1.4% of Velan Capital Investment Management LP's investment portfolio, making the stock its 14th largest holding. Velan Capital Investment Management LP owned approximately 0.74% of Perspective Therapeutics at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd acquired a new stake in shares of Perspective Therapeutics during the 4th quarter valued at about $33,000. Aigen Investment Management LP acquired a new stake in shares of Perspective Therapeutics during the 4th quarter valued at about $34,000. National Bank of Canada FI grew its position in shares of Perspective Therapeutics by 549,900.0% during the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock valued at $35,000 after acquiring an additional 10,998 shares during the period. ProShare Advisors LLC grew its position in shares of Perspective Therapeutics by 49.1% during the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock valued at $49,000 after acquiring an additional 5,011 shares during the period. Finally, Vontobel Holding Ltd. acquired a new stake in shares of Perspective Therapeutics during the 4th quarter valued at about $51,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Trading Down 4.8%

CATX stock traded down $0.12 during trading on Friday, hitting $2.39. The stock had a trading volume of 656,911 shares, compared to its average volume of 1,036,003. Perspective Therapeutics, Inc. has a twelve month low of $1.60 and a twelve month high of $16.70. The company's 50-day moving average price is $2.24 and its two-hundred day moving average price is $3.38.

Insider Buying and Selling

In other Perspective Therapeutics news, Director Robert F. Williamson III bought 38,145 shares of the firm's stock in a transaction on Monday, March 31st. The shares were acquired at an average cost of $2.14 per share, with a total value of $81,630.30. Following the purchase, the director now directly owns 108,982 shares of the company's stock, valued at $233,221.48. This trade represents a 53.85% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Juan Graham bought 33,333 shares of the firm's stock in a transaction on Friday, March 28th. The stock was acquired at an average cost of $2.25 per share, for a total transaction of $74,999.25. Following the completion of the purchase, the chief financial officer now directly owns 35,354 shares in the company, valued at approximately $79,546.50. This represents a 1,649.33% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have bought 115,696 shares of company stock worth $256,344. Insiders own 3.72% of the company's stock.

Analyst Upgrades and Downgrades

CATX has been the topic of a number of analyst reports. Brookline Capital Management upgraded Perspective Therapeutics to a "strong-buy" rating in a research report on Monday, March 10th. HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Perspective Therapeutics in a research report on Monday, March 31st. Lifesci Capital upgraded Perspective Therapeutics to a "strong-buy" rating in a research report on Thursday, March 6th. Truist Financial dropped their target price on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Finally, Scotiabank assumed coverage on Perspective Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price objective on the stock. One analyst has rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Perspective Therapeutics presently has a consensus rating of "Buy" and an average price target of $12.50.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.